Exam Drugs Flashcards
1
Q
Cyclophosphamide
A
- Chemotherapy Agent
- Mechanism:
- alkylating agent: forms DNA cross links resulting in inhibition of DNA synthesis and function
- Require bioactivation by the liver
- Major toxicities:
- Acute: (GI): Nausea and vomitting
- Delayed: moderate depression of peripheral blood count
- Excessive doses: severe bone marrow depression and hemorrhagic cystitis (hematuria and bladder pain)
2
Q
Cisplatin
A
- Chemotherapy Agent
- Mechanism: alkylating agent
- “stick” to the DNA strands
- Cytotoxic in all stages of cell cycle
- Toxocities
- Acute: highly emetogenic
- nausea and vomitting
- Delayed: nephrotoxicity, ototoxicity, irreversible nerve dysfunction
- Acute: highly emetogenic
3
Q
Nitrosourea: Carmustine
A
- Chemotherapy Agent
- Mechanism:
- Alkylating agent: DNA cross linking
- Able to enter CNS
- Toxicity:
- Acute: GI
- Delayed: Myelosuppression
4
Q
Procarbazine
A
- Chemotherapy Agent
- Mechanism
- Non-classic alkylating agent
- inhibits DNA, RNA and protein synthesis
- Toxicities:
- High risk for second malignancy
- Adverse drug-drug interactions due to MAOI metabolite activity
5
Q
Methotrexate
A
- Chemotherapy Agent
- Mechanism: Anti-metabolite: blocks synthesis of base pairs
- Folic acid analog: binds and inhibits DHFR and TS
- Maximum effect in S phase
- Toxicities
- Myelosuppression: neutropenia and thrombocytopenia
- Effects are reveresed by Leucovorin: reduced folate
6
Q
5-FU
A
- Mechanism: antimetabolite: pyrimidine analog
- block synthesis of base pairs
- works best in S phase
- Toxicities
- Toxicity severe in patients with low or absent dihydropyridine dehydrogenase (DPD)
- DPD is the enzyme that degrades this trug
- Myelosuppression
- Nausea, vomitting, diarrhea, mucositis (painful inflammation and ulceration of the mucous membranes lining the digestive tract)
- Toxicity severe in patients with low or absent dihydropyridine dehydrogenase (DPD)
7
Q
Capecitabine (highly likely to get tested)
A
- Chemotherapy agent
- Mechanism: antimetabolite: pyrimidine analog
- blocks synthesis of base pairs
- Pro-pro drug of 5-FU
- 2 attachments so that its not broken down in the GI
- ORALLY ACTIVE
-
Toxicity: Reflects continuous infusion
- Hand-foot syndrome
- redness, swelling, and pain on the palms of the hands and/or the soles of the feet
- Diarrhea
- Low risk of alopecia (hair falling out)
- Hand-foot syndrome
8
Q
Cladribine
A
- Chemotherapy Agent
- Mechanism: Purine analog
- inhibits DNA sythesis and repair by inhibiting ribonucleotide reductase
- Toxicity:
- Myelosupression
- Nausea and vomitting
- Immunosupression: CD4 and CD8 T cells
9
Q
6-Meracaptopurine
A
- Chemotherapy Agent
- Mechanism: Purine Antagonist
- inhibits enzyme of purine synthesis
- Incorporated into both DNA and RNA
- Toxicities:
- 6-MP is deactivated by xanthine oxidase
- Allopurinol is a potent xanthine oxidase inhibitor leading to excessive toxicity if given together
- Thiopurine methyl transferase (TPMT) deficiency can result in severe toxicities
- Myelosuppression
- Diarrhea
- 6-MP is deactivated by xanthine oxidase
10
Q
Vincristine
A
- Chemotherapy Agent
- Mechanism: Natural Product chemotherapeutic
- Vinca alkaloid: cause microtubule disfunction
- spindles provide a foundation/matrix so that the two sets of DNA can separate along these tracks and get folded within the cells and then have normal dividing cells
- when disrupt this, wipes out the cell
- Vinca alkaloid: cause microtubule disfunction
- Toxicity:
- Neurotoxicity with peripheral neuropathy
- Autonomic system dysfunction: orthostatic hypotension, urinary retention, paralytic ileus
- SIADH
11
Q
Paclitaxel
A
- Chemotherapeutic Agent
- Mechanism
- Taxane: cause microtubule disfunction by enhancing microtubule polymerization
- spindles provide a foundation/matrix so that the two sets of DNA can separate along these tracks and get folded within the cells and then have normal dividing cells
- when disrupt this, wipes out the cell
- Toxicity:
- Acute: Hypersensitivity
- Delayed: Neurotoxicity, peripheral sensory neuropathy
12
Q
Abraxane
A
- Chemotherapy Agent
- Mechanism:
- Taxane: cause microtubule disfunction by enhancing microtubule polymerization
- when disrupt this, wipes out the cell
- spindles provide a foundation/matrix so that the two sets of DNA can separate along these tracks and get folded within the cells and then have normal dividing cells
- Paclitaxel protein bound or albumin bound
- Avoids hypersensitivity
- Taxane: cause microtubule disfunction by enhancing microtubule polymerization
- Toxicity: decreased toxicity overall
13
Q
Irinotecan
A
- Natural Product Chemo
- Mechanism: Camptothecins:
- Topoisomerase 1 inhibitor
- essential for DNA replication as it cuts and relegates single stranded DNA strands
- inhibition causes DNA arrest
- results in S phase arrest
- Prodrug converted in liver
- prevents breakdown before getting to the cancer cells
- Topoisomerase 1 inhibitor
- Toxicity:
- Serious diarrhea
- Early: cholinergic event
- Late: 2-10 d post treatment, can be severe
- Bone marrow suppression
- Serious diarrhea
14
Q
Doxorubicin
A
- Antibiotic: Anthracyclines
- inhibit Topoisomerase II
- high affinity DNA intercalation
- blocks both DNA and RNA synthesis
- Generate semi-quinone free-radicals
- Major mechanism of cardiotoxicity
- Binds to cell membranes and alters fluidity and iron transport
- Toxicity:
- Cardiotoxicity
- Acute (2-3 d) arrhythmias, conduction abnormalities
- Chronic: dose dependent dilated cardiomyopathy
- Treating patients with Dexrazoxane, an iron-chelator, can reduce events in high risk patients
- Cardiotoxicity
15
Q
Bleomycin
A
- Antibiotic
- Binds DNA and causes SS and DS breaks
- inhibits DNA synthesis
- G2 phase arrest
- Toxicity:
- Pulmonary
16
Q
Mitomycin C
A
- antibiotic
- Mechanism:
- Needs to be reduced (works on tumor cells that create hypoxic environment)
- Acts during all cell cycle stages
- Toxicity:
- Nausea and vomitting
- Hemolytic Uremic Syndrome
17
Q
Imatinib
A
- Tyrosine Kinase Inhibitor
- Hematologic Disease: Chronic Myelongous Leukemia (CML)
- Has t(9;22) that creates BCR-ABL philadelphia chromsome
- Blocks out the effect of the Philadelphia chromosome
- Target:
- binds to catalytic cleft of ABL to stop BCR-ABL fusion protein from forming
- Also inhibits PDGF-R and c-KIT
- Toxicities:
- Resistance occurs when mutations in the cleft limit ability of Imatinib to bind
18
Q
ATRA/arsenic
A
- Target: Retinoic Acid Receptor
- Mechanism: displaces PML-RAR fusion protein preventing acute differential arrest of cells
- Hematologic disease:
- Acute Promyelocytic Leukemia (APML)
- Toxocity:
-
ATRA syndrome
- Leukocytosis: high neutrophil count
- Capillary leak syndrome: pulmonary edema, respiratory failure
- Renal failure
- Often used togeth with steroids, chemo and supportive care
- Occurs shortly after initiation of ATRA therapy in APML
-
ATRA syndrome
19
Q
Rituximab (Rituxan)
A
- Chimeric monoclonal antibody
- Target: CD20 on pre-B cells and mature B cells
- Hematologic Disease:
- B cell malignancies
- Autoimmune Diseases
- Nonhodgkin lymphoma
20
Q
Crizotinib
A
- Mechanism: Tyrosine Kinase Inhibitor
- Inhibits ALK, ROS1, HGFR and other Tyrosine Kinases
- Given to those with Nonsmall cell Lung Cancer
21
Q
Thalidomide
A
- Mechanism: unclear
- Hematologic Disease: Multiple Myeloma
- Toxicity:
- terratogenic: focomelia (short limbs)
22
Q
Trastuzumab (Herceptin)
A
- Monocolonal antibody
- Mechanism: binds to HER2 receptor, not allowing dimerization and thus preventing signaling
- Toxicity:
- Cardiac toxicity
23
Q
Cetuximab (Erbitux)
A
- Engineered chimeric monoclonal antibody to EGF-R
- Modest clinical activity in head and neck cancers
- K-RAS and BRAF mutations are associated with lack of response to Cetuximab
24
Q
Erlotinib
A
- Mechanism: Tyrosine Kinase Inhibitor
- Targets:
- EGF-R (human epidermal growth factor receptor)
25
Q
Bevacizumab
A
- Monoclonal antibody for colonrectal cancer
- Mechanism: Inhibits VEGFR
- VEGF is an important growth factor for endothelial cells (angiogenesis)
- Target: VEGFR
- Hematologic Disease: Multiple Myeloma
- Toxicity:
- Pulmonary hemorrhage: high risk in patients with squamous cell cancers
- hypertension, pulmonary hemorrhage, proteinuria
- Financial toxicity (expensive)
26
Q
Vemurafinib
A
- Mechanism: small molecule RAF inhibitor
- Target: targets V600E BRAF mutation
- Hematologic Disease: Melanoma and others
- Toxicity:
- Causes other skin cancers
- Resistance in colon cancer with V600E
27
Q
Bortezomib (Velcade)
A
- Mechanism: proteosome inhibitor
- Hematologic Disease: Multiple Myeloma
- Toxicity:
- neuropathy and myelosuppression
28
Q
Nivolumab
A
- Mechanism: PD-L1 inhibitor
- Binds to programmed death receptor-1 (PD-1) which inhibits programmed T cell death activity
- Reverses T cell suppression and induces antitumor response
- Hematologic Disease: Hodgkin Lymphoma
- Toxicity:
- Immune mediated pneumonitis, colitis, hepatitis, endorinopathies
- Fatigue, rash, musculoskeletal pain, pruritis (itchy skin)